Dhruv J Patel1, Waseem Lutfi2, Patrick Sweigert3, Emanuel Eguia3, Gerard Abood3, Lawrence Knab3, Paul C Kuo4, Marshall S Baker5. 1. Loyola University Chicago Stritch School of Medicine, USA. 2. University of Pittsburgh School of Medicine, USA. 3. Department of Surgery, Loyola University Medical Center, USA. 4. Department of Surgery, University of South Florida, USA. 5. Department of Surgery, Loyola University Medical Center, USA. Electronic address: marshall.baker@lumc.edu.
Abstract
BACKGROUND: Prior studies of adjuvant systemic therapy in pancreatic acinar cell carcinoma have been underpowered. METHODS: We queried the National Cancer Data Base to identify patients presenting with resectable (clinical stage I and II) acinar cell carcinoma between 2004 and 2015. Multivariable Cox Regression was used to evaluate the association between overall survival and systemic therapy. RESULTS: 298 patients met inclusion criteria: 38 received no treatment; 60 received systemic therapy alone; 84 received surgical resection alone; 116 underwent resection followed by adjuvant systemic therapy. On univariate analysis, resection was associated with a survival benefit compared to no treatment and systemic therapy alone (3-year overall survival: 57% vs. 26%, p < 0.001). On Cox analysis, use of adjuvant therapy was associated with a survival benefit compared to resection alone (HR 0.54, 95% CI: 0.33-0.89). CONCLUSIONS: Adjuvant therapy is associated with a significant survival benefit in patients with resectable acinar cell carcinoma.
BACKGROUND: Prior studies of adjuvant systemic therapy in pancreatic acinar cell carcinoma have been underpowered. METHODS: We queried the National Cancer Data Base to identify patients presenting with resectable (clinical stage I and II) acinar cell carcinoma between 2004 and 2015. Multivariable Cox Regression was used to evaluate the association between overall survival and systemic therapy. RESULTS: 298 patients met inclusion criteria: 38 received no treatment; 60 received systemic therapy alone; 84 received surgical resection alone; 116 underwent resection followed by adjuvant systemic therapy. On univariate analysis, resection was associated with a survival benefit compared to no treatment and systemic therapy alone (3-year overall survival: 57% vs. 26%, p < 0.001). On Cox analysis, use of adjuvant therapy was associated with a survival benefit compared to resection alone (HR 0.54, 95% CI: 0.33-0.89). CONCLUSIONS: Adjuvant therapy is associated with a significant survival benefit in patients with resectable acinar cell carcinoma.
Authors: Paul R Burchard; Alexander C Chacon; Alexa Melucci; Anthony S Casabianca; Subir Goyal; Jeffrey M Switchenko; Shishir K Maithel; David A Kooby; Darren R Carpizo; Mihir M Shah Journal: J Surg Oncol Date: 2022-01-07 Impact factor: 3.454
Authors: Lena Dreikhausen; Nadine Schulte; Sebastian Belle; Philip Weidner; Johannes Moersdorf; Christoph Reissfelder; Matthias P Ebert; Tianzuo Zhan Journal: Visc Med Date: 2021-03-29
Authors: Ekaterina Petrova; Joachim Wellner; Anne K Nording; Rüdiger Braun; Kim C Honselmann; Louisa Bolm; Richard Hummel; Monika Klinkhammer-Schalke; Sylke Ruth Zeissig; Kees Kleihues van Tol; Sylvia Timme-Bronsert; Peter Bronsert; Sergey Zemskov; Tobias Keck; Ulrich Friedrich Wellner Journal: Cancers (Basel) Date: 2021-12-04 Impact factor: 6.639
Authors: S M Haenen; J A M G Tol; S C J van Steen; O R Busch; A Farine Sarasqueta; S Roshani; A Wolkerstorfer; M M D van der Linden; J W Wilmink; H C Post; M G Besselink Journal: J Med Case Rep Date: 2022-10-05